OncoMatch/Clinical Trials/NCT07454382
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Is NCT07454382 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Elranatamab-bcmm and Cyclophosphamide for multiple myeloma.
Treatment: Elranatamab-bcmm · Cyclophosphamide — The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory drug (thalidomide, lenalidomide, pomalidomide)
At least 1 IMiD (thalidomide, lenalidomide or pomalidomide)
Must have received: proteasome inhibitor (bortezomib, carfilzomib, ixazomib)
At least 1 PI (bortezomib, carfilzomib or ixazomib)
Must have received: anti-CD38 monoclonal antibody (daratumumab, isatuximab)
At least 1 anti-CD38 monoclonal antibody (daratumumab or isatuximab)
Cannot have received: CD3 redirecting bispecific or trispecific antibody
Previous treatment with a CD3 redirecting bispecific or trispecific antibody for multiple myeloma
Cannot have received: autologous stem cell transplant
Exception: within 8 weeks prior to enrollment
History of autologous stem cell transplant within 8 weeks prior to enrollment
Cannot have received: allogeneic stem cell transplant
Exception: within 12 weeks prior to enrollment
history of allogeneic stem cell transplant within 12 weeks prior to enrollment
Lab requirements
Blood counts
ANC ≥ 1,000 cells/mm3 (use of G-CSF is permitted if completed at ≥7 days prior to planned start of study treatment); Platelets ≥ 25,000 cells/mm3 (transfusion support is permitted); Hemoglobin ≥ 8 g/dl (transfusion support is permitted)
Kidney function
Creatinine clearance (CrCL) of ≥15 mL/min by the CKD-EPI formula, Cockcroft-Gault formula, or with direct measurement
Liver function
Total bilirubin ≤ 1.5 x institutional ULN (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled); AST and ALT ≤3 x institutional ULN
Cardiac function
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function
Adequate hematologic function... Adequate renal function... Adequate hepatic function... Adequate cardiac function...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify